Core Viewpoint - Investors are expected to focus on Sol-Gel Technologies, Ltd.'s compliance with Nasdaq requirements and pipeline developments during the upcoming fourth-quarter and full-year 2024 results announcement [1]. Financial Performance - The Zacks Consensus Estimate for the upcoming quarter's revenues is $2 million, with an expected loss of 11 cents per share [1][12]. - Over the past year, Sol-Gel's shares have decreased by 46.2%, contrasting with a 1.9% increase in the industry [2]. Product Development - Sol-Gel has developed Twyneo and Epsolay, both FDA-approved treatments for acne vulgaris and rosacea, respectively [4]. - The company has licensing agreements for Twyneo and Epsolay, which generate royalties and milestone payments [4]. - Sol-Gel is also collaborating with Padagis for the development of a generic version of Zoryve Cream [5]. Revenue Sources - The company's revenue is primarily derived from licensing agreements with partners such as Padagis, Galderma, and Searchlight Pharma, with expectations of increased licensing revenues in the upcoming quarter [5]. Pipeline Candidates - The key pipeline candidate, SGT-610, is in phase III development for Gorlin Syndrome, with top-line data expected in the second half of 2026 [6]. - A proof-of-concept study for SGT-210, aimed at treating Darier disease, is also underway [6]. Compliance and Regulatory Updates - In November 2024, Sol-Gel received a notification from Nasdaq regarding the transfer of its shares to The Nasdaq Capital Market due to non-compliance with the Minimum Bid Price Requirement, with an additional 180 days granted to regain compliance [9]. Earnings Surprise History - Sol-Gel has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 41.93% [10].

Core Viewpoint - The article emphasizes the importance of value investing and highlights SolGel Technologies (SLGL) as a strong value stock based on its financial metrics and Zacks Rank [2][3][6] Company Summary - SolGel Technologies (SLGL) currently holds a Zacks Rank of 2 (Buy) and has received an "A" grade in the Value category, indicating it is among the strongest value stocks available [3] - The stock's price-to-book (P/B) ratio is 1.32, which is significantly lower than the industry average of 3.77, suggesting that SLGL may be undervalued [4] - Over the past 52 weeks, SLGL's P/B ratio has fluctuated between a high of 1.32 and a low of 0.29, with a median of 0.63 [4] - The price-to-sales (P/S) ratio for SLGL is 2.33, which is also lower than the industry's average P/S of 2.78, reinforcing the notion of potential undervaluation [5] - The combination of these valuation metrics and a strong earnings outlook positions SLGL as an impressive value stock at present [6]

Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that rising earnings estimates can lead to higher stock prices [4][6]. - For the fiscal year ending December 2024, Sol-Gel Technologies is expected to earn -$0.56 per share, reflecting a 44.6% change from the previous year's reported number [8]. Analyst Sentiment and Market Position - Analysts have been increasing their earnings estimates for Sol-Gel Technologies, with a 2.6% rise in the Zacks Consensus Estimate over the past three months [8]. - The upgrade to Zacks Rank 2 places Sol-Gel Technologies in the top 20% of Zacks-covered stocks, indicating strong potential for near-term price appreciation [11]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns for top-ranked stocks [7][9]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, while the next 15% are rated as 'Buy', highlighting the selectivity and effectiveness of the rating system [9][10].

Core Insights - Sol-Gel Technologies Ltd. reported a quarterly loss of $0.01 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.13, and an improvement from a loss of $0.21 per share a year ago, indicating a 92.31% earnings surprise [1] - The company achieved revenues of $5.36 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 99.29%, compared to revenues of $0.21 million in the same quarter last year [2] - Sol-Gel Technologies shares have declined approximately 54.8% year-to-date, contrasting with the S&P 500's gain of 24.7% [3] Financial Performance - Over the last four quarters, Sol-Gel Technologies has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $1.83 million, and for the current fiscal year, it is -$0.57 on revenues of $8.5 million [7] Industry Outlook - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Sol-Gel Technologies' stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

Core Insights - Sol-Gel Technologies, Ltd. has appointed Mori Arkin as interim CEO effective January 1, 2025, replacing founder Dr. Alon Seri-Levy, who will continue as a consultant for at least one year [2] - The company is conducting a Phase 3 clinical trial of SGT-610 for Gorlin Syndrome, with over 40 clinical sites activated and top-line results expected in the second half of 2026 [2][4] - Financial results for Q3 2024 show total revenue of $5.4 million, a significant increase from $0.2 million in Q3 2023, primarily driven by licensing revenue [5] Corporate Developments - The transfer of Sol-Gel's Ordinary Shares from The Nasdaq Global Market to The Nasdaq Capital Market was approved, effective November 15, 2024, to provide a second 180-day compliance period for the minimum bid price rule [2] - A new agreement with Padagis will enhance Sol-Gel's cash position by approximately $6 million through eight quarterly payments and low single-digit royalties from sales of a generic drug product [2] - Sol-Gel signed a license agreement for the commercialization of TWYNEO and EPSOLAY in South Korea, with expected upfront and regulatory milestone payments of up to $3.7 million [2] Clinical Trials and Product Pipeline - The Phase 3 study of SGT-610 is ongoing with approximately 140 subjects enrolled across 40 clinical centers, targeting a market exceeding $300 million annually if approved [2][4] - The proof-of-concept study for SGT-210 in patients with Darier disease is also ongoing, with a market potential estimated between $200 million to $300 million [2][4] - SGT-210 is currently being used in a compassionate use treatment for a pediatric patient, showing promising preliminary results [3] Financial Performance - Research and development expenses for Q3 2024 were $4.8 million, slightly up from $4.7 million in Q3 2023, primarily due to increased clinical trial expenses [6] - General and administrative expenses decreased to $1.4 million from $1.9 million in the same period last year, attributed to cost-saving measures [7] - The net loss for Q3 2024 was $0.4 million, a significant improvement compared to a net loss of $5.7 million in Q3 2023 [8] Cash Position - As of September 30, 2024, Sol-Gel had $14.6 million in cash and cash equivalents, and $14.6 million in marketable securities, totaling $29.2 million [8] - The company expects its cash resources to fund operations into the first quarter of 2026 [8]

Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has experienced a recent downtrend, losing 8.4% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings outlook from analysts [1]. Group 1: Technical Analysis - A hammer chart pattern was formed in the last trading session, indicating that bulls may have countered the bears, suggesting potential support for the stock [1]. - The hammer pattern signals a possible bottom in a downtrend, indicating that selling pressure may be exhausting [2]. - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors, but should be combined with other bullish indicators for confirmation [2]. Group 2: Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SLGL, with a 31.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating expected better earnings [3]. - SLGL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [3]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a trend reversal [3].

Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Sol-Gel Technologies indicates a positive outlook on its earnings, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [5][7]. - Rising earnings estimates for Sol-Gel Technologies suggest an improvement in the company's underlying business, which should lead to higher stock prices as investors recognize this trend [6]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Sol-Gel Technologies' upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]. Earnings Estimate Data - For the fiscal year ending December 2024, Sol-Gel Technologies is expected to earn -$0.57 per share, reflecting a year-over-year change of 43.6% [9]. - Over the past three months, the Zacks Consensus Estimate for Sol-Gel Technologies has increased by 31.3%, indicating a positive trend in earnings expectations [9].

Core Insights - Sol-Gel Technologies is extending its cash runway into Q1 2026 following recent transactions and cost-cutting measures [1] - The company is conducting a Phase 3 clinical trial for SGT-610 targeting Gorlin Syndrome, with topline results expected by Q2 2026 [1][2] - Sol-Gel has signed multiple licensing agreements for its products TWYNEO and EPSOLAY in Europe and South Africa, with plans for further expansion into Latin America and other regions [2][5] Financial Performance - Total revenue for Q2 2024 was $5.4 million, a significant increase from $0.6 million in Q2 2023 [6] - Research and development expenses decreased to $2.4 million from $5.3 million in the same period last year, attributed to various cost-saving measures [7] - The company reported a net income of $1.9 million for Q2 2024, compared to a net loss of $6.0 million in Q2 2023 [8] Clinical Developments - The Phase 3 study for SGT-610 is ongoing with approximately 140 subjects involved, and results are anticipated in Q2 2026 [2][5] - A proof-of-concept study for SGT-210 in Darier disease is also in progress, targeting a market potential of $200 million to $300 million [3][5] Management Changes - Mr. Mori Arkin is set to become the interim CEO as of January 1, 2025, pending shareholder approval, following a management realignment [4] - The current CEO, Dr. Alon Seri-Levy, will step down at the end of 2024 but will continue as a consultant for at least one year [4] Licensing and Market Expansion - Sol-Gel has signed six initial license agreements for TWYNEO and EPSOLAY, expecting upfront and milestone payments of up to $3.7 million [2] - The company anticipates launching TWYNEO and EPSOLAY in new territories by 2027 and 2026, respectively, with projected annual royalty revenues starting at $1 million to $2 million in 2026 and growing to approximately $10 million by 2030 [2]

Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 135%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.23, delivering a surprise of -53.33%. Over the last four quarters, ...

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Topline results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product gen ...